10 tidbits of investor intel — or, what Adam and Damian learned this week in New York

No Comments

first_img What is it? STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Mario Tama/Getty Images @adamfeuerstein Adam Feuerstein GET STARTED [email protected] Business Log In | Learn More About the Authors Reprints Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED National Biotech Reporter Damian covers biotech, is a co-writer of The Readout newsletter, and a co-host of “The Readout LOUD” podcast.center_img @damiangarde What’s included? Senior Writer, Biotech Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He’s also a co-host of “The Readout LOUD” podcast. 10 tidbits of investor intel — or, what Adam and Damian learned this week in New York NEW YORK — As biotech speeds through a make-or-break September, a gaggle of banking conferences brought investors here this week, in hopes of separating the lucrative ideas from the lost causes.We came, too, stalking the conference hallways (and open bars) in markedly less expensive clothing to take the pulse of biotech financiers in the middle of a hugely important time for the sector. Here, some scattered observations on biotech’s hottest topics: Damian Garde Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. [email protected] By Adam Feuerstein and Damian Garde Sept. 14, 2017 Reprints Tags cancerdementiapolicyrare diseaseSTAT+White Housewomen’s healthlast_img

Leave a Reply

Your email address will not be published. Required fields are marked *